Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Valuation & Earnings
This table compares Fate Therapeutics and Aprea Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $6.65 million | 38.74 | -$136.32 million | ($1.05) | -2.05 |
| Aprea Therapeutics | $290,000.00 | 26.27 | -$12.60 million | ($1.08) | -0.56 |
Analyst Ratings
This is a breakdown of recent recommendations for Fate Therapeutics and Aprea Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 3 | 4 | 0 | 2.38 |
| Aprea Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Fate Therapeutics currently has a consensus target price of $5.90, indicating a potential upside of 174.42%. Aprea Therapeutics has a consensus target price of $3.07, indicating a potential upside of 406.89%. Given Aprea Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Fate Therapeutics.
Profitability
This table compares Fate Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -65.08% | -41.73% |
| Aprea Therapeutics | N/A | -47.60% | -40.97% |
Insider and Institutional Ownership
97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
Summary
Aprea Therapeutics beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
